Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.
The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.
If you registered for the live program, please find your complimentary OnDemand access under "My Courses."
Target Audience
This activity is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.
Learning Objectives
At the conclusion of this activity, learners will be better able to:
- Review the genetics, pathophysiology, and diagnosis of hypertrophic cardiomyopathy.
- Discuss the clinical trial data and optimal use of current and emerging treatment options for the management of patients with hypertrophic cardiomyopathy.
- Identify advanced treatment options for the management of challenging patients with hypertrophic cardiomyopathy.
Content Outline
Remembering the Basics: Diagnosis, Pathophysiology, and Genetics (Including the Family)
Sharlene Day, MD
Management: The Usual Approach
Carolyn Y. Ho, MD
New Kids on the Block: New Medications and Future Approaches
Victoria Parikh, MD
What Happens When the Usual is Not Enough: Referral and Advanced Therapy
Lynne Warner Stevenson, MD
Case Presentation: Mild LV Systolic Dysfunction
Michael Ayers, MD
What Happens When the Usual is Not Enough
Lynne Warner Stevenson, MD, FHFSA
Panel Discussion
All Faculty
Related Resource(s)
View complete program information.
Supporters
The Heart Failure Society of America acknowledges Bristol Myers Squibb and Cytokinetics for providing an independent educational grant to support the Heart Failure Seminar: Focus Hypertrophic Cardiomyopathy (HCM).
Important Date(s)
Originally recorded November, 2023